GÖRG Partnerschaft von Rechtsanwälten mbB, led by Frankfurt partner Dr. Markus Söhnchen, has advised the venture capital fund coparion GmbH & Co. KG on the sale of its stake in Cardior Pharmaceuticals to Novo Nordisk.
Novo Nordisk acquires Cardior Pharmaceuticals GmbH for a total amount of up to 1.025 billion euros.
Cardior Pharmaceuticals is a leading company specialising in the discovery and development of therapies that use RNA (ribonucleic acid) to prevent, repair and reverse heart disease. Non-coding RNA molecules will be used to target the causes of heart disorders with the aim of permanently eliminating them. The agreement covers Cardior's lead product candidate CDR132L, which was originally based on research results from the Hannover Medical School (MHH), including in collaboration with the Max Planck Institute for Biophysical Chemistry in Göttingen (now the Max Planck Institute for Multidisciplinary Natural Sciences). It is currently in phase 2 clinical development for the treatment of heart failure.
Cardior's lead product candidate CDR132L has a unique mode of action and the potential to become a completely novel therapeutic approach aimed at halting or partially reversing the progression of the disease in people with heart failure. CDR132L is designed to specifically block abnormal levels of the microRNA molecule miR-132, which could potentially lead to long-lasting improvements in heart function.
Completion of the acquisition is subject to receipt of the relevant regulatory approvals and other customary conditions and is expected to occur in the second quarter of 2024.
Advisors coparion GmbH & Co. KG
GÖRG Partnerschaft von Rechtsanwälten mbB
Dr. Markus Söhnchen (Lead Partner, M&A / Corporate Law, Frankfurt)
Dr. Adalbert Rödding, LL.M. (Partner, Tax, Cologne)
Dr. Gerhard Gündel (Counsel, M&A / Corporate Law, Frankfurt)
Timo Jans (Associate, M&A / Corporate Law, Frankfurt)
Sven Uetermeyer, LL.M. (Lund) (Associate, Tax, Frankfurt)
